LT-626

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLT-626
Drug Alias NamePARP inhibitor (BioMarin Pharmaceuticals/Stanford University)LT-626
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitors
TargetsPoly (ADP-Ribose) polymerase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiomarin Pharmaceutical IncStanford University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A